Arbutus Biopharma (ABUS) Announces 2024 Corporate Objectives and Provides Financial Update streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Additional data from two on-going Phase 2a clinical trials evaluating imdusiran, our RNAi therapeutic, as a cornerstone therapy in combination with other compounds expected in 2024 Initiation of a.
Cash runway anticipated to be extended from Q2 2025 to Q4 2025Data from multiple Phase 1 and 2 clinical trials expected in 2024 OXFORD, United Kingdom, Jan. 05, 2024 Barinthus Biotherapeutics.
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.